Patients

Lenabasum

Multi-system Inflammatory

Systemic Sclerosis

Preclinical Phase 1 Phase 2 Phase 3 Launch
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase in progress
Launch Phase not started

Targeting 2021 launch

Multi-system Inflammatory

Dermatomyositis

Preclinical Phase 1 Phase 2 Phase 3 Launch
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase in progress
Launch Phase not started

Multi-system Inflammatory

Systemic Lupus Erythematosus

Preclinical Phase 1 Phase 2 Phase 3 Launch
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Launch Phase not started
Preclinical Phase 1 Phase 2 Phase 3 Launch
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Launch Phase not started

CRB-4001

Preclinical Phase 1 Phase 2 Phase 3 Launch
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Launch Phase not started

Scheduled to Enter Phase 1 in 2019, NIH Committed to Funding Phase 2 Study.

Preclinical library (more than 600 compounds)

Goal: 1-2 new Phase 1 programs per year starting in 2020

Preclinical Phase 1 Phase 2 Phase 3 Launch
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Launch Phase not started

Lenabasum is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

To learn more about each of our ongoing studies, please click on one of the below links.